Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/30107| Title: | Real-world tolerability of venetoclax-based maintenance therapy with azole antifungal prophylaxis for acute myeloid leukemia in remission. | Austin Authors: | Nguyen, Phillip C;Donati, Vanessa;Vassili, Catherine;Grigg, Andrew P ;Tiong, Ing S | Affiliation: | Olivia Newton-John Cancer Research Institute Clinical Haematology Department of Clinical Hematology, Alfred Hospital and Monash University, Melbourne, Australia |
Issue Date: | May-2022 | Date: | 2022-03-27 | Publication information: | Leukemia Research 2022; 116: 106837 | URI: | https://ahro.austin.org.au/austinjspui/handle/1/30107 | DOI: | 10.1016/j.leukres.2022.106837 | ORCID: | 0000-0001-5743-3171 0000-0001-7417-4343 |
Journal: | Leukemia Research | PubMed URL: | 35400541 | PubMed URL: | https://pubmed.ncbi.nlm.nih.gov/35400541/ | Type: | Journal Article | Subjects: | AML Tolerability Toxicity Venetoclax |
| Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.